New hope for kids with juvenile arthritis: Real-World drug study launches
NCT ID NCT07211932
Summary
This study will look at how well the medication tofacitinib works for children and teenagers with juvenile idiopathic arthritis (JIA) in real-world medical settings. It will follow 58 participants under 18 years old for 12 months to see if the drug improves their arthritis control. The main goal is to measure changes in their arthritis disease activity score.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JUVENILE IDIOPATHIC ARTHRITIS (JIA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Corporació Sanitària Parc Taulí de Sabadell
Sabadell, Barcelona, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital Sant Joan de Déu Barcelona
Barcelona, Barcelona, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital de Vilafranca
Vilafranca del Penedès, Barceona, 08720, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.